Skip to main content
OpenTrials

Clinical trial condition

Smoldering Multiple Myeloma

Explore clinical trials studying Smoldering Multiple Myeloma. Study availability and eligibility vary by location and protocol.

77 public trials 28 recruiting studies
Refine in advanced search Browse all conditions

Smoldering Multiple Myeloma trial results

Active, Not Recruiting

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

NCT00114101

Conditions
Blood Protein Disorders, Cardiovascular Diseases, DS Stage I Multiple Myeloma, +19 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • UC San Diego Medical Center - Hillcrest San Diego, California, United States
View all 140 locations
View Trial Details
Active, Not Recruiting

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

NCT05014646

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • Atrium Health University City/LCI-University Charlotte, North Carolina, United States
View Trial Details
Active, Not Recruiting

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

NCT05955508

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations
  • Hospital Clinico Universitario Santiago de Compostela Santiago de Compostela, A Coruna, Spain
  • Hospital Universitario Virgen de las Nieves Granada, Andalusia, Spain
  • Hospital Universitari Son Llatzer Palma Mallorca, Balearic Islands, Spain
  • Hospital Germans Trias i Pujol Badalona, Barcelona, Spain
View all 17 locations
View Trial Details
Active, Not Recruiting

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

NCT03236428

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations
  • Pacific Cancer Care Monterey, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
View Trial Details
Active, Not Recruiting

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

NCT02886065

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Weill Cornell Medical College New York, United States
View Trial Details
Active, Not Recruiting

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

NCT04850846

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations
  • Brigham and Women's Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Dana-Farber at Brighton Brighton, Massachusetts, United States
  • Dana-Farber at Merrimack Valley Methuen, Massachusetts, United States
View Trial Details

Related conditions